Previous 10 | Next 10 |
Gainers: NeuroSense (NRSN) +333%. BitNile (NILE) +69%. Yumanity Therapeutics (YMTX) +50%. BT Brands (BTBD) +41%. Mullen Automotive (MULN) +39%. Hudson Capital (HUSN) +38%. O2Micro International (OIIM) +32%. Cenntro Electric Group (CENN) +33%. Akanda (AKAN) +29%. Anaplan (PLAN) +28%. Losers: V...
Gainers: NeuroSense Therapeutics (NRSN) +289%. Yumanity Therapeutics (YMTX) +36%. Dermata Therapeutics (SERA) +30%. Sera Prognostics (DRMA) +21%. Creative Medical Technology Holdings (CELZ) +20%. Losers: Vallon Pharmaceuticals (VLON) -70%. Connect Biopharma Holdings (CNTB) -22%. Imm...
StoneCo (STNE) +29% on Q4 results. Kidpik (PIK) +22%. Sunshine Biopharma (SBFM) +16%. Yumanity Therapeutics (YMTX) +12%. On Holding (ONON) +9% on Q4 results. Hycroft Mining Holding (HYMC) +9%. PagSeguro Digital (PAGS) +8%. Houston American Energy (HUSA) +8%. Zhihu (ZH) +8%...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Yumanity Therapeutics (NASDAQ:YMTX) has added ~2% in the pre-market on Thursday after the company announced plans to reduce nearly 60% of its workforce by April as part of a strategic restructuring of its business. In addition, Yumanity (YMTX) announced it is evaluating strategic al...
BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today announced that it is exploring strategic a...
Gainers: BioCardia BCDA +32%. Biophytis BPTS +17%. Mersana Therapeutics MRSN +7%. Liquidia (NASDAQ:LQDA) +5%. Vaccitech (NASDAQ:VACC) +3%. Losers: Kiromic BioPharma KRBP -17%. Mainz Biomed (NASDAQ:MYNZ) -9%. Vaccinex (NASDAQ:VCNX) -7%. NeuroBo Phar...
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today announced that, in response to its IND app...
Yumanity achieves research milestone in its collaboration with Merck; Yumanity to receive $5 million milestone payment Michael J. Fox Foundation awards grant to accelerate early proof-of-concept testing of promising Parkinson’s disease therapy BOSTON, Jan. 11, 2022 ...
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., Pr...